INSIGHTS INTO THE ROLE OF INJECTABLE PLATELET-RICH FIBRIN (I-PRF) IN TEMPOROMANDIBULAR JOINT (TMJ) DISORDERS: A COMPREHENSIVE REVIEW

Background: Temporomandibular joint (TMJ) disorders are a diverse group of conditions that affect the joint and associated muscles, leading to significant pain, functional limitations, and reduced quality of life. Traditional treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, and surgical interventions, often provide limited relief and are not always well-tolerated. Objective: This review aims to evaluate the current evidence on the efficacy of injectable platelet-rich fibrin (i-PRF) as a treatment for TMJ disorders, exploring its potential as a less invasive alternative to conventional therapies. Methods: A comprehensive search of the literature was conducted, focusing on recent studies and systematic reviews that investigate the use of i-PRF for TMJ disorders. Key databases were searched for relevant articles, and studies were selected based on their relevance and methodological quality. Results: Recent research indicates that i-PRF, a modern platelet concentrate derived from the patients own blood, may offer substantial benefits for treating TMJ disorders such as osteoarthritis, disc displacement, and dysfunction. Evidence suggests that i-PRF could significantly reduce pain and improve functional outcomes. The regenerative properties of platelets and growth factors in i-PRF contribute to enhanced tissue healing and reduced inflammation, potentially offering a viable alternative to traditional treatments. Conclusion:i-PRF appears to be a promising, less invasive option for managing TMJ disorders, with potential advantages over conventional therapies. However, further studies are needed to confirm its effectiveness, optimize treatment protocols, and address any limitations in the current research. This review consolidates recent findings and assesses the potential of i-PRF to advance the field of joint therapy.